129 related articles for article (PubMed ID: 37253389)
1. NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
Le MK; Vuong HG; Nguyen TTT; Kondo T
J Neuropathol Exp Neurol; 2023 Jun; 82(7):650-658. PubMed ID: 37253389
[TBL] [Abstract][Full Text] [Related]
2. NAA10 gene expression is associated with mesenchymal transition, dedifferentiation, and progression of clear cell renal cell carcinoma.
Duong NX; Nguyen T; Le MK; Sawada N; Kira S; Kondo T; Inukai T; Mitsui T
Pathol Res Pract; 2024 Mar; 255():155191. PubMed ID: 38340582
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Lysine Acetyltransferase Activity of Recombinant Human ARD1/NAA10.
Vo TTL; Park JH; Lee EJ; Nguyen YTK; Han BW; Nguyen HTT; Mun KC; Ha E; Kwon TK; Kim KW; Jeong CH; Seo JH
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013195
[TBL] [Abstract][Full Text] [Related]
4. N-α-acetyltransferase 10 (NAA10) in development: the role of NAA10.
Lee MN; Kweon HY; Oh GT
Exp Mol Med; 2018 Jul; 50(7):1-11. PubMed ID: 30054454
[TBL] [Abstract][Full Text] [Related]
5. NAA10 as a New Prognostic Marker for Cancer Progression.
Kim SM; Ha E; Kim J; Cho C; Shin SJ; Seo JH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126484
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylation of the Acetyltransferase NAA10 Trp38 Is Not an Enzyme-Switch in Human Cells.
Ree R; Krogstad K; McTiernan N; Jakobsson ME; Arnesen T
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769235
[TBL] [Abstract][Full Text] [Related]
7. iTRAQ and two-dimensional-LC-MS/MS reveal NAA10 is a potential biomarker in esophageal squamous cell carcinoma.
Wang D; Chen J; Han J; Wang K; Fang W; Jin J; Xue S
Proteomics Clin Appl; 2022 May; 16(3):e2100081. PubMed ID: 35182098
[TBL] [Abstract][Full Text] [Related]
8. NAA10-related syndrome.
Wu Y; Lyon GJ
Exp Mol Med; 2018 Jul; 50(7):1-10. PubMed ID: 30054457
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal Acetyltransferase Naa10/ARD1 Does Not Acetylate Lysine Residues.
Magin RS; March ZM; Marmorstein R
J Biol Chem; 2016 Mar; 291(10):5270-7. PubMed ID: 26755727
[TBL] [Abstract][Full Text] [Related]
10. NAA10 promotes proliferation of renal cell carcinoma by upregulating UPK1B.
Zhang ZY; Zhang JL; Zhao LX; Yang Y; Guo R; Zhou N; Liu YR; Zheng GP
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11553-11560. PubMed ID: 33275221
[TBL] [Abstract][Full Text] [Related]
11. ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications.
Lee D; Jang MK; Seo JH; Ryu SH; Kim JA; Chung YH
Exp Mol Med; 2018 Jul; 50(7):1-12. PubMed ID: 30054466
[TBL] [Abstract][Full Text] [Related]
12. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10.
Yang H; Li Q; Niu J; Li B; Jiang D; Wan Z; Yang Q; Jiang F; Wei P; Bai S
Oncotarget; 2016 Jan; 7(3):2709-20. PubMed ID: 26646451
[TBL] [Abstract][Full Text] [Related]
13. A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy.
Støve SI; Blenski M; Stray-Pedersen A; Wierenga KJ; Jhangiani SN; Akdemir ZC; Crawford D; McTiernan N; Myklebust LM; Purcarin G; McNall-Knapp R; Wadley A; Belmont JW; Kim JJ; Lupski JR; Arnesen T
Eur J Hum Genet; 2018 Sep; 26(9):1294-1305. PubMed ID: 29748569
[TBL] [Abstract][Full Text] [Related]
14.
Kweon HY; Lee MN; Dorfel M; Seo S; Gottlieb L; PaPazyan T; McTiernan N; Ree R; Bolton D; Garcia A; Flory M; Crain J; Sebold A; Lyons S; Ismail A; Marchi E; Sonn SK; Jeong SJ; Jeon S; Ju S; Conway SJ; Kim T; Kim HS; Lee C; Roh TY; Arnesen T; Marmorstein R; Oh GT; Lyon GJ
Elife; 2021 Aug; 10():. PubMed ID: 34355692
[TBL] [Abstract][Full Text] [Related]
15. A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly.
Ree R; Geithus AS; Tørring PM; Sørensen KP; Damkjær M; ; Lynch SA; Arnesen T
BMC Med Genet; 2019 Jun; 20(1):101. PubMed ID: 31174490
[TBL] [Abstract][Full Text] [Related]
16. Biochemical analysis of novel NAA10 variants suggests distinct pathogenic mechanisms involving impaired protein N-terminal acetylation.
McTiernan N; Tranebjærg L; Bjørheim AS; Hogue JS; Wilson WG; Schmidt B; Boerrigter MM; Nybo ML; Smeland MF; Tümer Z; Arnesen T
Hum Genet; 2022 Aug; 141(8):1355-1369. PubMed ID: 35039925
[TBL] [Abstract][Full Text] [Related]
17. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
18. Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Zheng J; Wang F; Yang Y; Xu J; Yang J; Wang K; Liu Y; Du G; Zeng Y
J Oral Pathol Med; 2019 Sep; 48(8):686-695. PubMed ID: 31134698
[TBL] [Abstract][Full Text] [Related]
19. The N-end rule pathway enzyme Naa10 supports epiblast specification in mouse embryonic stem cells by modulating FGF/MAPK.
Takekoshi D; Tokuzawa Y; Sakanaka M; Kato H
In Vitro Cell Dev Biol Anim; 2019 May; 55(5):355-367. PubMed ID: 30993557
[TBL] [Abstract][Full Text] [Related]
20. Naa10p promotes cell invasiveness of esophageal cancer by coordinating the c-Myc and PAI1 regulatory axis.
Pan KF; Liu YC; Hsiao M; Cheng TY; Hua KT
Cell Death Dis; 2022 Nov; 13(11):995. PubMed ID: 36433943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
